Hypercalcemia may indicate cancer
the ONA take:
According to a new study published in the British Journal of Cancer, hypercalcemia in men was linked with an increased risk for developing cancer within 1 year of detecting elevated blood levels of calcium.
For the study, researchers from the Centre for Academic Primary Care at the University of Bristol in Bristol, United Kingdom, sought to determine whether elevated levels of calcium in the blood could be utilized as an early screening method for the diagnosis of cancer.
The researchers identified 54,000 patients in an electronic database and analyzed their medical records to look for patients with a history of hypercalcemia that were later diagnosed with cancer. They found that men with a calcium level of 2.6 to 2.8 mmol/L (normal calcium level is 2.1 to 2.5 mmol/L) had an 11.5% increased risk of a cancer diagnosis within 1 year of identifying the elevated calcium level. Men with a calcium level greater than 2.8 mmol/L had a 28% increased risk.
Women had an increased risk for a cancer diagnosis as well, but the effect was smaller than men. Furthermore, hypercalcemiia was associated with bowel, breast, leukemia, lung, myeloma, and prostate cancer.
Hypercalcemia in men was linked with an increased risk for developing cancer.
Calcium in the blood could provide an early warning of certain cancers, especially in men, research has shown. Even slightly raised blood levels of calcium in men was associated with an increased risk of cancer diagnosis within one year.
The discovery, reported in the British Journal of Cancer, raises the prospect of a simple blood test to aid the early detection of cancer in high risk patients. Hypercalcaemia - a higher than normal calcium reading - was associated with a wide range of cancers, chiefly lung, prostate, breast, bowel, and those affecting the blood such as leukaemia and myeloma.
While the condition was already known to occur in up to a fifth of cancer patients, this is the first time it has been shown to pre-date diagnosis.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|